News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daiichi Sankyo, Inc. (4568.t), Eli Lilly and Company (LLY) Say Heart Drug Effient Fails to Meet Goal in a Phase III Trial


8/27/2012 7:16:06 AM

Daiichi Sankyo Co., Ltd. (DSKYF, DSNKY) and Eli Lilly and Co. (LLY:Quote) Sunday announced that their new heart drug Effient (prasugrel) failed to beat the older product Plavix (clopidogrel). The study named TRILOGY ACS did not meet primary objective of demonstrating prasugrel superiority over clopidogrel. Daiichi Sankyo and Eli Lilly co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd. "While this is not the outcome we anticipated, we believe this study contributes to the knowledge base about ACS patients who are medically managed," said Glenn Gormley, Global Head of Research & Development and Senior Executive Officer, Daiichi Sankyo.

Read at RTT News
Read at Fox News
Read at Chicago Tribune
Read at Reuters
Read at Pharmaceutical Business Review


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES